BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeng Q, Jewell CM. Directing toll-like receptor signaling in macrophages to enhance tumor immunotherapy. Curr Opin Biotechnol 2019;60:138-45. [PMID: 30831487 DOI: 10.1016/j.copbio.2019.01.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Li C, Xu X, Wei S, Jiang P, Xue L, Wang J; Senior Correspondence. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. J Immunother Cancer 2021;9:e001341. [PMID: 33504575 DOI: 10.1136/jitc-2020-001341] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Liang ZQ, Zhong LY, Li J, Shen JH, Tu XY, Zhong ZH, Zeng JJ, Chen JH, Wei ZX, Dang YW, Huang SN, Chen G. Clinicopathological significance and underlying molecular mechanism of downregulation of basonuclin 1 expression in ovarian carcinoma. Exp Biol Med (Maywood) 2021;:15353702211052036. [PMID: 34644201 DOI: 10.1177/15353702211052036] [Reference Citation Analysis]
3 Mainini F, De Santis F, Fucà G, Di Nicola M, Rivoltini L, Eccles M. Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against Cancer. Cancers (Basel) 2021;13:3765. [PMID: 34359665 DOI: 10.3390/cancers13153765] [Reference Citation Analysis]
4 Pahlavanneshan S, Sayadmanesh A, Ebrahimiyan H, Basiri M. Toll-Like Receptor-Based Strategies for Cancer Immunotherapy. J Immunol Res 2021;2021:9912188. [PMID: 34124272 DOI: 10.1155/2021/9912188] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Raggi F, Bosco MC. Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1). Cancers (Basel) 2020;12:E1337. [PMID: 32456204 DOI: 10.3390/cancers12051337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Rodell CB, Ahmed MS, Garris CS, Pittet MJ, Weissleder R. Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy. Theranostics 2019;9:8426-36. [PMID: 31879528 DOI: 10.7150/thno.35434] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 11.3] [Reference Citation Analysis]
7 Andrea AE, Chiron A, Mallah S, Bessoles S, Sarrabayrouse G, Hacein-Bey-Abina S. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment. Front Immunol 2022;13:830292. [PMID: 35211124 DOI: 10.3389/fimmu.2022.830292] [Reference Citation Analysis]
8 Shan H, Dou W, Zhang Y, Qi M. Targeted ferritin nanoparticle encapsulating CpG oligodeoxynucleotides induces tumor-associated macrophage M2 phenotype polarization into M1 phenotype and inhibits tumor growth. Nanoscale 2020;12:22268-80. [PMID: 33146206 DOI: 10.1039/d0nr04520a] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
9 Quinones Tavarez Z, Li D, Croft DP, Gill SR, Ossip DJ, Rahman I. The Interplay Between Respiratory Microbiota and Innate Immunity in Flavor E-Cigarette Vaping Induced Lung Dysfunction. Front Microbiol 2020;11:589501. [PMID: 33391205 DOI: 10.3389/fmicb.2020.589501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Deng K, Yang D, Zhou Y. Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy. Pharmaceutics 2022;14:1344. [DOI: 10.3390/pharmaceutics14071344] [Reference Citation Analysis]
11 Zhang H, Zhu T, Fu R, Peng Y, Jing P, Xu W, Wang H, Li S, Shu Z, Yin Y, Zhang X. Combination of Detoxified Pneumolysin Derivative ΔA146Ply and Berbamine as a Treatment Approach for Breast Cancer. Mol Ther Oncolytics 2020;18:247-61. [PMID: 32728613 DOI: 10.1016/j.omto.2020.06.015] [Reference Citation Analysis]
12 Zhan L, Liu X, Zhang J, Cao Y, Wei B. Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy. Oncol Lett 2020;20:2075-90. [PMID: 32782525 DOI: 10.3892/ol.2020.11774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Qu N, Wang X, Meng Y, Shan F. Prospective oncotarget for gynecological cancer: Opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis. Int Immunopharmacol 2019;75:105723. [PMID: 31408839 DOI: 10.1016/j.intimp.2019.105723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Hua Y, Wu J, Wu H, Su C, Li X, Ao Q, Zeng Q, Zhu X, Zhang X. Exposure to hydroxyapatite nanoparticles enhances Toll-like receptor 4 signal transduction and overcomes endotoxin tolerance in vitro and in vivo. Acta Biomater 2021;135:650-62. [PMID: 34525415 DOI: 10.1016/j.actbio.2021.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
15 Zeng Q, Wang R, Hua Y, Wu H, Chen X, Xiao Y, Ao Q, Zhu X, Zhang X. Hydroxyapatite nanoparticles drive the potency of Toll-like receptor 9 agonist for amplified innate and adaptive immune response. Nano Res . [DOI: 10.1007/s12274-022-4683-x] [Reference Citation Analysis]
16 Rodell CB, Koch PD, Weissleder R. Screening for new macrophage therapeutics. Theranostics 2019;9:7714-29. [PMID: 31695796 DOI: 10.7150/thno.34421] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
17 Dai X, Ren L, Liu M, Cai H, Zhang H, Gong Q, Gu Z, Luo K. Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy. Nano Today 2021;39:101163. [DOI: 10.1016/j.nantod.2021.101163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lin A, Xu W, Luo P, Zhang J. Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma. Front Pharmacol 2021;12:721181. [PMID: 34721019 DOI: 10.3389/fphar.2021.721181] [Reference Citation Analysis]
19 Roth GA, Saouaf OM, Smith AAA, Gale EC, Hernández MA, Idoyaga J, Appel EA. Prolonged Codelivery of Hemagglutinin and a TLR7/8 Agonist in a Supramolecular Polymer-Nanoparticle Hydrogel Enhances Potency and Breadth of Influenza Vaccination. ACS Biomater Sci Eng 2021;7:1889-99. [PMID: 33404236 DOI: 10.1021/acsbiomaterials.0c01496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Yuan L, Wu X, Zhang L, Yang M, Wang X, Huang W, Pan H, Wu Y, Huang J, Liang W, Li J, Zhu X, Wang S, Guan J, Liu L. SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma. Cancer Immunol Immunother 2021. [PMID: 34181042 DOI: 10.1007/s00262-021-02995-4] [Reference Citation Analysis]
21 Chini CCS, Peclat TR, Gomez LS, Zeidler JD, Warner GM, Kashyap S, Mazdeh DZ, Hayat F, Migaud ME, Paulus A, Chanan-khan AA, Chini EN. Dihydronicotinamide Riboside Is a Potent NAD+ Precursor Promoting a Pro-Inflammatory Phenotype in Macrophages. Front Immunol 2022;13:840246. [DOI: 10.3389/fimmu.2022.840246] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Dacoba TG, Anfray C, Mainini F, Allavena P, Alonso MJ, Torres Andón F, Crecente-Campo J. Arginine-Based Poly(I:C)-Loaded Nanocomplexes for the Polarization of Macrophages Toward M1-Antitumoral Effectors. Front Immunol 2020;11:1412. [PMID: 32733469 DOI: 10.3389/fimmu.2020.01412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
23 Bahramabadi R, Dabiri S, Iranpour M, Kazemi Arababadi M. TLR4: An Important Molecule Participating in Either Anti-Human Papillomavirus Immune Responses or Development of Its Related Cancers. Viral Immunol 2019;32:417-23. [PMID: 31721657 DOI: 10.1089/vim.2019.0061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]